<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04910126</url>
  </required_header>
  <id_info>
    <org_study_id>ACTS</org_study_id>
    <nct_id>NCT04910126</nct_id>
  </id_info>
  <brief_title>Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma</brief_title>
  <official_title>Doxorubicin（A）Plus Camrelizumab(C) Versus Doxorubicin Alone for the First-line Treatment(T) of Select Type of Adcanced Soft Tissue Sarcoma(ACTS): a Randomised Controlled Multi Centers Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of the combination of adriamycin and Camrelizumab in the&#xD;
      first-line treatment of advanced soft tissue sarcoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">November 12, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 12, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>up to three years</time_frame>
    <description>progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to three years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR Objective Response Rate（ORR）</measure>
    <time_frame>up to one year</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>up to two years</time_frame>
    <description>Duration of Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>up to three years</time_frame>
    <description>treatment related adverse events, TRAEs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Neoplasms, Connective and Soft Tissue</condition>
  <condition>Sarcoma Metastatic</condition>
  <condition>Sarcoma,Soft Tissue</condition>
  <arm_group>
    <arm_group_label>experiment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adriamycin and Camrelizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adriamycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab 200mg q3w up to 2 years</description>
    <arm_group_label>experiment group</arm_group_label>
    <other_name>C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin</intervention_name>
    <description>adriamycin 20mg/m2 d1-3 q3w maximum 6 cycles</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>experiment group</arm_group_label>
    <other_name>A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - 1) Patients with advanced soft tissue sarcoma (pathologically confirmed undifferentiated&#xD;
        pleomorphic sarcoma/synovial sarcoma/leiomyosarcoma/liposarcoma) not suitable for surgery;&#xD;
        2) Aged ≥ 18 years old, &lt; 60 years old; 3) Eastern Cooperative Oncology Group (ECOG)&#xD;
        performance status score of 0-1, amputees can be 0-2; 4) Expected survival &gt; 6 months; 5)&#xD;
        Adequate organ and bone marrow function, defined as follows: ① Blood routine (14 days&#xD;
        before screening without blood transfusion, without G-CSF, without drug correction):&#xD;
        neutrophil count (ANC) ≥ 1.5 × 10^9/L; platelet count (PLT) ≥ 100 × 10^9/L; hemoglobin (Hb)&#xD;
        ≥ 100 g/L; ② Blood biochemistry: serum creatinine (Cr) ≤ 1.5 × upper limit of normal (ULN)&#xD;
        or creatinine clearance ≥ 60ml/min; total bilirubin (TBIL) ≤ 1.5 × ULN; aspartate&#xD;
        aminotransferase (AST) or alanine aminotransferase (ALT) level ≤ 2.5 × ULN, The subjects&#xD;
        with liver metastasis should be ≤ 5 × ULN; ③ Coagulation function: international normalized&#xD;
        ratio (INR) ≤ 1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤&#xD;
        1.5 × ULN; ④ Urinalysis: urine protein &lt; 2 +; if urine protein ≥ 2 +, the 24-hour urine&#xD;
        protein quantification must be ≤ 1g; ⑤ thyroid stimulating hormone (TSH) ≤ ULN and ≥ LLN;&#xD;
        if abnormal, T3 and T4 levels should be investigated, normal T3 and T4 levels can be&#xD;
        included.&#xD;
&#xD;
        6) ECG is basically normal, no myocardial ischemia performance, no history of arrhythmia&#xD;
        requiring drug intervention, echocardiography LVEF ≥ 50%; 7) no autoimmune diseases; 8) can&#xD;
        provide tissue samples for biological testing; 9) have measurable lesions according to&#xD;
        RECIST1.1 criteria; 10）Agree and have signed informed consent, willing and able to comply&#xD;
        with scheduled visits, study treatment, laboratory tests and other test procedures.^&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) Patients who have previously received anthracycline treatment; 2) Patients who have&#xD;
             previously received immunotherapy such as anti-PD-1, anti-PD-L1, anti-PD-L2,&#xD;
             anti-CTLA4, etc.; 3) Patients who are known to be allergic to recombinant humanized&#xD;
             anti-PD-1 monoclonal antibody drugs and their components; 4) Patients with New York&#xD;
             Heart Association (NYHA) score of more than II heart disease (including grade II); 5)&#xD;
             Patients with mental or neurological disorders or do not cooperate; 6) Patients who&#xD;
             have received other anti-tumor therapy 4 weeks before enrollment, including but not&#xD;
             limited to surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.;&#xD;
             7) Patients who have used immunosuppressive drugs within 14 days before enrollment.&#xD;
             Does not include nasal spray and inhaled corticosteroids or physiological doses of&#xD;
             systemic steroids (i.e., no more than 10 mg/day prednisolone or other corticosteroids&#xD;
             at physiological doses of the same drug); 8) any active autoimmune disease or history&#xD;
             of autoimmune disease (subjects with vitiligo or asthma that has been completely&#xD;
             relieved in childhood and currently does not require medical intervention can be&#xD;
             included), or known history of allogeneic organ transplantation or allogeneic&#xD;
             hematopoietic stem cell transplantation.&#xD;
&#xD;
             9) Known allergy to the study drug or any of its excipients; or severe allergic&#xD;
             reactions to other monoclonal antibodies; 10) Patients with central nervous system&#xD;
             metastasis; 11) Patients with severe systemic infection (who need intravenous&#xD;
             antibiotics, antifungal or antiviral drugs) within 4 weeks before enrollment, or body&#xD;
             temperature ≥ 38.0℃; 12) Patients received live vaccination within 4 weeks before the&#xD;
             start of treatment; 13) HIV infection, HCV antibody positive and HCV RNA higher than&#xD;
             the lower limit of detection of the analytical method, HBsAg or HBcAb positive and HBV&#xD;
             DNA positive (quantitative detection limit of 500 IU/ml); 14) History of active&#xD;
             pulmonary tuberculosis; 15) Patients who had been diagnosed with any other malignant&#xD;
             tumor within 3 years before enrollment, except for adequately treated basal cell or&#xD;
             squamous cell skin cancer or cervical carcinoma in situ; 16) Pregnant women or&#xD;
             lactating women, or patients who plan to become pregnant during the study period or&#xD;
             within one year after the use of the study drug; 17) Patients who participating in the&#xD;
             trial is not in their best interest (such as endangering their health) or will hinder&#xD;
             the evaluation of the trial protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Chen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Chen, MD, PhD</last_name>
    <phone>0086-027-85872987</phone>
    <email>chenjingwh@hust.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Union Hospital，Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jieying Zhang</last_name>
      <phone>0086-027-85872987</phone>
      <email>whxhzjy@hust.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>Jing Chen</investigator_full_name>
    <investigator_title>Director, Head of Sarcoma Department , Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neoplasms, Connective and Soft Tissue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

